Back to top
more

TRACON Pharmaceuticals (TCON)

(Delayed Data from NSDQ)

$2.11 USD

2.11
350,315

-0.18 (-7.86%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $2.13 +0.02 (0.95%) 7:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for TCON

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

TRACON Pharmaceuticals, Inc. [TCON]

Reports for Purchase

Showing records 1 - 20 ( 68 total )

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/06/2024

Company Report

Pages: 6

4Q23 Results; Pivotal ENVASARC Trial Expected to Complete Enrollment This Month; Lowering PT by $1

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

12/20/2023

Daily Note

Pages: 3

Update on Pivotal ENVASARC Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/20/2023

Company Report

Pages: 5

First Product Development Platform Deal Yields $3M Upfront Payment

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

11/10/2023

Company Report

Pages: 6

3Q23 Results; More Interim Data From ENVASARC Pivotal Phase 2 Trial Expected by YE23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

05/11/2023

Company Report

Pages: 8

1Q23 Results; ENVASARC Trial''s Second and Final Interim Analysis Expected in 3Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

04/25/2023

Company Report

Pages: 7

Arbitration Outcome Lengthens Cash Runway Guidance

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

03/09/2023

Company Report

Pages: 8

4Q22 Results; Next Interim Analysis From ENVASARC Study in 3Q23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

12/27/2022

Daily Note

Pages: 3

Up to $30 Million Non-Recourse Financing Agreement Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

12/14/2022

Daily Note

Pages: 3

Positive IDMC Interim Efficacy Review From the ENVASARC Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

11/21/2022

Daily Note

Pages: 3

First Patient Dosed in Phase 1/2 Trial of YH001 in Combination With Envafolimab and Doxorubicin in Front Line Sarcoma

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

11/15/2022

Company Report

Pages: 8

3Q22 Results; ENVASARC IDMC Efficacy Review Expected Later This Quarter

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

10/06/2022

Daily Note

Pages: 3

IDMC Review of 12 Week Safety Data From ENVASARC Study Results in Recommendation to Proceed as Planned

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

10/03/2022

Daily Note

Pages: 3

ICC Extends Time Limit For Decision in I-Mab Arbitration

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

09/14/2022

Daily Note

Pages: 3

Envafolimab Receives Fast Track Designation From FDA for UPS and MFS

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

08/29/2022

Daily Note

Pages: 3

FDA Approves IND for Phase 1/2 Trial of YH001 in Combination With Envafolimab and Doxorubicin in Sarcoma Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

08/11/2022

Company Report

Pages: 8

2Q22 Results; First Interim Efficacy Data From Pivotal Envafolimab Trial Expected 4Q22

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

08/08/2022

Daily Note

Pages: 3

YH001 IND Submitted to the FDA

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

07/26/2022

Daily Note

Pages: 3

Pivotal ENVASARC Trial Doses 36th Patient, Triggering Initial IDMC Efficacy Review to Proceed

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

06/15/2022

Daily Note

Pages: 4

Time Limit Extended Until September 30, 2022, For Final Decision in Ongoing Arbitration

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: TRACON Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

05/12/2022

Company Report

Pages: 7

1Q22 Results; Two Interim Safety Reviews and Interim Efficacy Data Expected for Pivotal ENVASARC Trial in 2H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party